Similar articles for PMID: 31221100

Year	Number of Results
1997	1
1999	1
2003	1
2006	2
2007	3
2008	2
2009	1
2010	3
2011	8
2012	7
2013	12
2014	20
2015	22
2016	22
2017	27
2018	30
2019	27
2020	36
2021	48
2022	45
2023	14
2024	2

1

Adverse drug reactions in South African patients receiving bedaquiline-containing tuberculosis treatment: an evaluation of spontaneously reported cases.

Jones J, Mudaly V, Voget J, Naledi T, Maartens G, Cohen K. Jones J, et al. BMC Infect Dis. 2019 Jun 20;19(1):544. doi: 10.1186/s12879-019-4197-7. BMC Infect Dis. 2019. PMID: 31221100 Free PMC article.

2

Adverse drug reactions reported to a provincial public health sector pharmacovigilance programme in South Africa.

Jones J, Swart A, Tommy E, Cohen K, Stewart A, Voget J, Blockman M. Jones J, et al. S Afr Med J. 2020 Nov 27;110(12):1226-1230. doi: 10.7196/SAMJ.2020.v110i12.14721. S Afr Med J. 2020. PMID: 33403970

3

Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety.

Gao JT, Du J, Wu GH, Pei Y, Gao MQ, Martinez L, Fan L, Chen W, Xie L, Chen Y, Wang H, Jin L, Li GB, Zong PL, Xiong Y, Wu QH, Li MW, Yan XF, Miao YF, Cai QS, Li XJ, Bai DP, Geng SJ, Yang GL, Tang PJ, Zeng Y, Chen XH, Li TX, Cai C, Zhou Y, Zhuo M, Wang JY, Guan WL, Xu L, Shi JC, Shu W, Cheng LL, Teng F, Ning YJ, Xie SH, Sun YX, Zhang LJ, Liu YH. Gao JT, et al. Infect Dis Poverty. 2021 Mar 19;10(1):32. doi: 10.1186/s40249-021-00819-2. Infect Dis Poverty. 2021. PMID: 33736710 Free PMC article.

4

Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study.

Schnippel K, Ndjeka N, Maartens G, Meintjes G, Master I, Ismail N, Hughes J, Ferreira H, Padanilam X, Romero R, Te Riele J, Conradie F. Schnippel K, et al. Lancet Respir Med. 2018 Sep;6(9):699-706. doi: 10.1016/S2213-2600(18)30235-2. Epub 2018 Jul 11. Lancet Respir Med. 2018. PMID: 30001994

5

Adverse Drug Reactions Reported to a National HIV & Tuberculosis Health Care Worker Hotline in South Africa: Description and Prospective Follow-Up of Reports.

Njuguna C, Stewart A, Mouton JP, Blockman M, Maartens G, Swart A, Chisholm B, Jones J, Dheda M, Igumbor EU, Cohen K. Njuguna C, et al. Drug Saf. 2016 Feb;39(2):159-69. doi: 10.1007/s40264-015-0359-8. Drug Saf. 2016. PMID: 26547719 Free PMC article.

6

Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.

Ferlazzo G, Mohr E, Laxmeshwar C, Hewison C, Hughes J, Jonckheere S, Khachatryan N, De Avezedo V, Egazaryan L, Shroufi A, Kalon S, Cox H, Furin J, Isaakidis P. Ferlazzo G, et al. Lancet Infect Dis. 2018 May;18(5):536-544. doi: 10.1016/S1473-3099(18)30100-2. Epub 2018 Feb 13. Lancet Infect Dis. 2018. PMID: 29452942

7

A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis.

Cohen K, Maartens G. Cohen K, et al. Expert Opin Drug Saf. 2019 Oct;18(10):875-882. doi: 10.1080/14740338.2019.1648429. Epub 2019 Aug 5. Expert Opin Drug Saf. 2019. PMID: 31339384 Review.

8

Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort Study.

Brust JCM, Gandhi NR, Wasserman S, Maartens G, Omar SV, Ismail NA, Campbell A, Joseph L, Hahn A, Allana S, Hernandez-Romieu AC, Zhang C, Mlisana K, Viljoen CA, Zalta B, Ebrahim I, Franczek M, Master I, Ramangoaela L, Te Riele J, Meintjes G. Brust JCM, et al. Clin Infect Dis. 2021 Dec 6;73(11):2083-2092. doi: 10.1093/cid/ciab335. Clin Infect Dis. 2021. PMID: 33882121 Free PMC article.

9

Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.

Centers for Disease Control and Prevention. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2013 Oct 25;62(RR-09):1-12. MMWR Recomm Rep. 2013. PMID: 24157696 Free article.

10

Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa.

Olayanju O, Limberis J, Esmail A, Oelofse S, Gina P, Pietersen E, Fadul M, Warren R, Dheda K. Olayanju O, et al. Eur Respir J. 2018 May 30;51(5):1800544. doi: 10.1183/13993003.00544-2018. Print 2018 May. Eur Respir J. 2018. PMID: 29700106 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

302 results

Results by year